Vesicular monoamine transporter 2 mediates fear behavior in mice.
Vesicular monoamine transporter 2 mediates fear behavior in mice.
复制标题
DOI:
10.1111/gbb.12634
复制
发表时间:
2020-06
期刊:
影响因子:
--
通讯作者:
Miller GW
中科院分区:
文献类型:
--
作者:
Branco RC;Burkett JP;Black CA;Winokur E;Ellsworth W;Dhamsania RK;Lohr KM;Schroeder JP;Weinshenker D;Jovanovic T;Miller GW
A subset of people exposed to a traumatic event develop post-traumatic stress disorder (PTSD), which is associated with dysregulated fear behavior. Genetic variation in SLC18A2, the gene that encodes vesicular monoamine transporter 2 (VMAT2), has been reported to affect risk for the development of PTSD in humans. Here, we use transgenic mice that express either 5% (VMAT2-LO mice) or 200% (VMAT2-HI mice) of wild-type levels of VMAT2 protein. We report that VMAT2-LO mice have reduced VMAT2 protein in the hippocampus and amygdala, impaired monoaminergic vesicular storage capacity in both the striatum and frontal cortex, decreased monoamine metabolite abundance, and a greatly reduced capacity to release dopamine upon stimulation. Furthermore, VMAT2-LO mice showed exaggerated cued and contextual fear expression, altered fear habituation, inability to discriminate threat from safety cues, altered startle response compared to wild-type mice, and an anxiogenic-like phenotype, but displayed no deficits in social function. By contrast, VMAT2-HI mice exhibited increased VMAT2 protein throughout the brain, higher vesicular storage capacity, and greater dopamine release upon stimulation compared to wild-type controls. Behaviorally, VMAT2-HI mice were similar to wild-type mice in most assays, with some evidence of a reduced anxiety-like responses. Together, these data demonstrate that presynaptic monoamine function mediates PTSD-like outcomes in our mouse model, and suggest a causal link between reduced VMAT2 expression and fear behavior, consistent with the correlational relationship between VMAT2 genotype and PTSD risk in humans. Targeting this system is a potential strategy for the development of pharmacotherapies for disorders like PTSD.
登录
查看更多内容
影响因子:
3.7
作者:
Flandreau, Elizabeth;Risbrough, Victoria;Lu, Ailing;Ableitner, Martin;Geyer, Mark A.;Holsboer, Florian;Deussing, Jan M.
通讯作者:
Deussing, Jan M.
影响因子:
4.7
作者:
Jovanovic T;Kazama A;Bachevalier J;Davis M
通讯作者:
Davis M
影响因子:
7.4
作者:
Glover, Ebony M.;Phifer, Justine E.;Crain, Daniel F.;Norrholm, Seth D.;Davis, Michael;Bradley, Bekh;Ressler, Kerry J.;Jovanovic, Tanja
通讯作者:
Jovanovic, Tanja
影响因子:
5.2
作者:
Eiden LE;Weihe E
通讯作者:
Weihe E
影响因子:
--
作者:
KESSLER, RC;SONNEGA, A;NELSON, CB
通讯作者:
NELSON, CB